Drugs / Conteltinib
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT02695550 | Mar 2016 → Mar 2018 | non-small cell lung carcinoma | Centaurus Biopharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Conteltinib | “Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies.” PMID 36424628 ↗ Nov 2022 |
| Known as | CT-707 | “Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies.” PMID 36424628 ↗ Nov 2022 |
| Action | Inhibit | “CT-707 is an inhibitor of ALK/focal adhesion kinase (FAK) and IGFR-1.” PMID 30381078 ↗ 20193“Insulin-like growth factor I receptor inhibitor” CHEMBL3899477 ↗ “Protein tyrosine kinase 2 beta inhibitor” CHEMBL3899477 ↗ “Focal adhesion kinase 1 inhibitor” CHEMBL3899477 ↗ |
| Modality | Small molecule | “Conteltinib (CT-707) is a potent second-generation anaplastic lymphoma kinase (ALK) tyrosine kinase inhibitor (TKI) showing promising anti-tumor activities in preclinical studies.” PMID 36424628 ↗ Nov 2022 |
| Route | Oral | “conteltinib was taken orally at doses of 50 to 800 mg quaque die (QD) in a dose-escalation phase.” PMID 36424628 ↗ Nov 2022 |
| Target | ALK | “CT-707 is an inhibitor of ALK/focal adhesion kinase (FAK) and IGFR-1.” PMID 30381078 ↗ 2019 |
| Target | IGF1R | “Insulin-like growth factor I receptor inhibitor” CHEMBL3899477 ↗ |
| Target | PTK2 | “Focal adhesion kinase 1 inhibitor” CHEMBL3899477 ↗ |
| Target | PTK2B | “Protein tyrosine kinase 2 beta inhibitor” CHEMBL3899477 ↗ |